Telix Pharmaceuticals TLX
NASDAQ TLX
$9.03 +0.04 (+0.44%)
At close: Oct 27, 2026 · 4:00 PM EDT

Telix Pharmaceuticals (TLX) Common Equity (2023 - 2026)

Updated

Telix Pharmaceuticals (TLX) reported Common Equity of $487.68 million for the quarter ended Jun 30, 2026.

Analysis

Telix Pharmaceuticals (TLX) Common Equity (2023 - 2026) Analysis & Trends

As of Dec 31, 2025, Telix Pharmaceuticals posted Common Equity of $415.38 million, up 17.7% from the prior year.

  • Common Equity has increased for three consecutive years, with a three-year compound annual growth rate of 95.5% (years ended Dec 2022 to Dec 2025).
  • By year, Common Equity came in at $352.94 million in the year ended Dec 31, 2024 (+243.8%), $102.65 million in the year ended Dec 31, 2023 (+84.6%) and $55.61 million in the year ended Dec 31, 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Eli Lilly 1,206.37 Bn 1,174.95 Bn 19.71 Bn 33.88 Bn
2 Johnson & Johnson 647.04 Bn 566.90 Bn 17.30 Bn 81.53 Bn
3 AbbVie 506.16 Bn 479.31 Bn 12.70 Bn -5.94 Bn
4 Merck 349.94 Bn 304.37 Bn 12.21 Bn 41.98 Bn
5 Novartis Ag 299.20 Bn 272.77 Bn - -
6 Astrazeneca 263.53 Bn 237.29 Bn 12.86 Bn 50.37 Bn
7 Amgen 242.16 Bn 197.56 Bn 7.24 Bn 11.69 Bn
8 Gilead Sciences 197.42 Bn 171.53 Bn 6.22 Bn 11.83 Bn
9 Pfizer 169.85 Bn 116.80 Bn 10.94 Bn 85.49 Bn
10 Telix Pharmaceuticals 3.06 Bn 2.02 Bn - 487.68 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 487.68 Mn
Dec 31, 2025 415.38 Mn
Dec 31, 2024 353.43 Mn
Dec 31, 2023 101.65 Mn
API Access

Telix Pharmaceuticals Common Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=common-equity&ticker=TLX&period=max&api_key=YOUR_API_KEY